Immunosuppressive mechanisms in glioblastoma

Edjah K. Nduom, Michael Weller, Amy B. Heimberger

Research output: Contribution to journalReview articlepeer-review

262 Scopus citations


Despite maximal surgical and medical therapy, the treatment of glioblastoma remains a seriously vexing problem, with median survival well under 2 years and few long-term survivors. Targeted therapy has yet to produce significant advances in treatment of these lesions in spite of advanced molecular characterization of glioblastoma and glioblastoma cancer stem cells. Recently, immunotherapy has emerged as a promising mode for some of the hardest to treat tumors, including metastatic melanoma. Although immunotherapy has been evaluated in glioblastoma in the past with limited success, better understanding of the failures of these therapies could lead to more successful treatments in the future. Furthermore, there is a persistent challenge for the use of immune therapy to treat glioblastoma secondary to the existence of redundant mechanisms of tumor-mediated immune suppression. Here we will address these mechanisms of immunosuppression in glioblastoma and therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)vii9-vii14
StatePublished - Nov 1 2015
Externally publishedYes


  • glioblastoma
  • immunosuppression
  • immunotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunosuppressive mechanisms in glioblastoma'. Together they form a unique fingerprint.

Cite this